In Q1 2026, West Pharmaceutical Services demonstrated solid operating momentum driven by strength in its proprietary products segment, particularly high-value elastomers and advanced injectable delivery devices. The company raised its full-year outlook supported by sustained demand from biologics and generic pharmaceutical customers despite ongoing supply chain complexities. West’s business model, rooted in integrated containment and delivery system offerings coupled with contract manufacturing services, underpins a durable competitive moat reinforced by regulatory barriers and global manufacturing scale. Challenges persist due to raw material inflation and regulatory compliance, but growth catalysts include expanded at-home injection adoption and connected health opportunities.